28087508|t|International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial
28087508|a|Regional differences in risk of diabetes mellitus and cardiovascular outcomes in people with impaired glucose tolerance are poorly characterized. Our objective was to evaluate regional variation in risk of new-onset diabetes mellitus, cardiovascular outcomes, and treatment effects in participants from the NAVIGATOR (Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research) trial. NAVIGATOR randomized people with impaired glucose tolerance and cardiovascular risk factors or with established cardiovascular disease to valsartan (or placebo) and to nateglinide (or placebo) with a median 5-year follow-up. Data from the 9306 participants were categorized by 5 regions: Asia (n=552); Europe (n=4909); Latin America (n=1406); North America (n=2146); and Australia, New Zealand, and South Africa (n=293). Analyzed outcomes included new-onset diabetes mellitus; cardiovascular death; a composite cardiovascular outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke; and treatment effects of valsartan and nateglinide. Respective unadjusted 5-year risks for new-onset diabetes mellitus, cardiovascular death, and the composite cardiovascular outcome were 33%, 0.4%, and 4% for Asia; 34%, 2%, and 6% for Europe; 37%, 4%, and 8% for Latin America; 38%, 2%, and 6% for North America; and 32%, 4%, and 8% for Australia, New Zealand, and South Africa. After adjustment, compared with North America, European participants had a lower risk of new-onset diabetes mellitus (hazard ratio 0.86, 95% CI 0.78-0.94; P=0.001), whereas Latin American participants had a higher risk of cardiovascular death (hazard ratio 2.68, 95% CI 1.82-3.96; P<0.0001) and the composite cardiovascular outcome (hazard ratio 1.48, 95% CI 1.15-1.92; P=0.003). No differential interactions between treatment and geographic location were identified. Major regional differences regarding the risk of new-onset diabetes mellitus and cardiovascular outcomes in NAVIGATOR participants were identified. These differences should be taken into account when planning global trials. URL: http://www.ClinicalTrials.gov. Unique identifier: NCT00097786.
28087508	27	35	Outcomes	T062	UMLS:C0086750
28087508	54	76	Cardiovascular Disease	T038	UMLS:C0007222
28087508	112	138	Impaired Glucose Tolerance	T038	UMLS:C0271650
28087508	140	148	Insights	T038	UMLS:C0233820
28087508	158	173	NAVIGATOR Trial	T033	UMLS:C0159069
28087508	198	223	risk of diabetes mellitus	T033	UMLS:C0580321
28087508	228	242	cardiovascular	T082	UMLS:C3887460
28087508	243	251	outcomes	T062	UMLS:C0086750
28087508	255	261	people	T098	UMLS:C0027361
28087508	267	293	impaired glucose tolerance	T038	UMLS:C0271650
28087508	350	358	regional	T082	UMLS:C0205147
28087508	409	423	cardiovascular	T082	UMLS:C3887460
28087508	424	432	outcomes	T062	UMLS:C0086750
28087508	438	455	treatment effects	T033	UMLS:C1518681
28087508	459	471	participants	T098	UMLS:C0679646
28087508	481	490	NAVIGATOR	T033	UMLS:C0159069
28087508	492	503	Nateglinide	T103	UMLS:C0903898
28087508	508	517	Valsartan	T103	UMLS:C0216784
28087508	521	547	Impaired Glucose Tolerance	T038	UMLS:C0271650
28087508	548	565	Outcomes Research	T062	UMLS:C0086750
28087508	567	572	trial	T033	UMLS:C0159069
28087508	574	583	NAVIGATOR	T033	UMLS:C0159069
28087508	584	594	randomized	T062	UMLS:C0034656
28087508	595	601	people	T098	UMLS:C0027361
28087508	607	633	impaired glucose tolerance	T038	UMLS:C0271650
28087508	686	708	cardiovascular disease	T038	UMLS:C0007222
28087508	712	721	valsartan	T103	UMLS:C0216784
28087508	726	733	placebo	T103	UMLS:C1696465
28087508	742	753	nateglinide	T103	UMLS:C0903898
28087508	758	765	placebo	T103	UMLS:C1696465
28087508	774	780	median	T082	UMLS:C2939193
28087508	788	797	follow-up	T058	UMLS:C1522577
28087508	818	830	participants	T098	UMLS:C0679646
28087508	853	860	regions	T082	UMLS:C0017446
28087508	862	866	Asia	T082	UMLS:C0003980
28087508	876	882	Europe	T082	UMLS:C0015176
28087508	893	906	Latin America	T082	UMLS:C0023122
28087508	917	930	North America	T082	UMLS:C0028405
28087508	945	954	Australia	T082	UMLS:C0004340
28087508	956	967	New Zealand	T082	UMLS:C0027978
28087508	973	985	South Africa	T082	UMLS:C0037712
28087508	1004	1012	outcomes	T062	UMLS:C0086750
28087508	1051	1065	cardiovascular	T082	UMLS:C3887460
28087508	1066	1071	death	T033	UMLS:C1306577
28087508	1085	1099	cardiovascular	T082	UMLS:C3887460
28087508	1100	1107	outcome	T062	UMLS:C0086750
28087508	1111	1125	cardiovascular	T082	UMLS:C3887460
28087508	1126	1131	death	T033	UMLS:C1306577
28087508	1142	1163	myocardial infarction	T038	UMLS:C0027051
28087508	1177	1183	stroke	T038	UMLS:C0038454
28087508	1189	1206	treatment effects	T033	UMLS:C1518681
28087508	1210	1219	valsartan	T103	UMLS:C0216784
28087508	1224	1235	nateglinide	T103	UMLS:C0903898
28087508	1305	1319	cardiovascular	T082	UMLS:C3887460
28087508	1320	1325	death	T033	UMLS:C1306577
28087508	1345	1359	cardiovascular	T082	UMLS:C3887460
28087508	1360	1367	outcome	T062	UMLS:C0086750
28087508	1395	1399	Asia	T082	UMLS:C0003980
28087508	1421	1427	Europe	T082	UMLS:C0015176
28087508	1449	1462	Latin America	T082	UMLS:C0023122
28087508	1484	1497	North America	T082	UMLS:C0028405
28087508	1523	1532	Australia	T082	UMLS:C0004340
28087508	1534	1545	New Zealand	T082	UMLS:C0027978
28087508	1551	1563	South Africa	T082	UMLS:C0037712
28087508	1597	1610	North America	T082	UMLS:C0028405
28087508	1612	1620	European	T098	UMLS:C0239307
28087508	1621	1633	participants	T098	UMLS:C0679646
28087508	1738	1752	Latin American	T098	UMLS:C1553378
28087508	1753	1765	participants	T098	UMLS:C0679646
28087508	1787	1801	cardiovascular	T082	UMLS:C3887460
28087508	1802	1807	death	T033	UMLS:C1306577
28087508	1874	1888	cardiovascular	T082	UMLS:C3887460
28087508	1889	1896	outcome	T062	UMLS:C0086750
28087508	1974	1981	between	T082	UMLS:C0205103
28087508	1996	2015	geographic location	T082	UMLS:C0017446
28087508	2114	2128	cardiovascular	T082	UMLS:C3887460
28087508	2129	2137	outcomes	T062	UMLS:C0086750
28087508	2141	2150	NAVIGATOR	T033	UMLS:C0159069
28087508	2151	2163	participants	T098	UMLS:C0679646
28087508	2151	2163	participants	T098	UMLS:C0679646
28087508	2249	2255	trials	T062	UMLS:C0008976